Your session is about to expire
← Back to Search
Pamrevlumab + Chemotherapy for Pancreatic Cancer (LAPIS Trial)
LAPIS Trial Summary
This trial is testing a new cancer treatment on people with pancreatic cancer that has spread and cannot be removed by surgery.
LAPIS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.LAPIS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My blood tests show enough platelets, hemoglobin, and neutrophils.I have not had major surgery in the last 4 weeks, except for biliary stent placement.I have had chemotherapy or radiation for pancreatic cancer.My pancreatic cancer cannot be surgically removed.I am a man or a woman not pregnant or breastfeeding.Women who could become pregnant need to have a negative pregnancy test before joining the study.I have a health condition that could make participating in this study risky.My diagnosis is pancreatic cancer, confirmed by lab tests.I cannot stop taking my medication that affects CYP2C8 or CYP3A4 enzymes.I am using or willing to use effective birth control during and for 6 months after the study.I have not had cancer, except for non-dangerous skin types or very early stage cancers, in the last 3 years.I have not received a live vaccine in the last 4 weeks.I am allergic to certain types of monoclonal antibody treatments.I am allergic to some chemotherapy drugs or their ingredients.I do not have any severe illnesses that could interfere with the study.Your disease can be measured using specific guidelines for imaging tests.I do not have severe heart, lung, diabetes, or neurological conditions.My kidney function is within the required range.I have a history of lung disease or hepatitis C, B, or HIV.I am 18 years old or older.My liver tests are within the required limits.I am fully active or can carry out light work.I have mild or no nerve damage in my hands and feet.
- Group 1: Arm A
- Group 2: Arm B
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the most similar medical trials to the one being conducted involving Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX?
"The original Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX trial was completed in 1997 at City of Hope Comprehensive Cancer Center. Out of the 2771 total trials since then, 1603 are still actively recruiting patients. A large number of these studies are based out of Ann Arbor, Michigan."
Have either of the following drug combinations been approved by the FDA: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX?
"This medical treatment combination has been evaluated in Phase 3 clinical trials, meaning that there is some data suggesting that it is effective and multiple rounds of data supporting its safety. Our team at Power rates the safety of this combination as a 3 on a scale from 1 to 3."
In how many different medical clinics is this clinical study being conducted today?
"With the majority of its operations based in University of Michigan (Ann Arbor, Michigan), Stony Brook University (Stony Brook, Texas) and Baylor College of Medicine (Houston, Connecticut), this clinical trial also has active outposts in 40 other locations."
What illnesses or conditions is the Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX treatment regimen meant for?
"Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX are the most common treatments for malignant neoplasms. However, these medical interventions can also be effective against non-small cell lung carcinoma, rectal carcinoma, and colorectal carcinoma."
Are we currently enrolling people for this trial?
"Unfortunately, this particular trial is not currently enrolling new patients. Although the posting was updated as recently as June 29th, 2022, the study is not seeking any more participants at this time. There are however, 2200 other trials which are actively recruiting right now."
How many people have signed up to participate in this experiment?
"This particular clinical trial is not presently enrolling patients. It was first posted on 5/10/2019, and the most recent update occurred on 6/29/2022. However, if you expand your search to include other trials, there are 600 clinical trials actively recruiting participants with nonresectable pancreatic cancer and 1603 trials for Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX that are currently enrolling patients."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger